Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into the Phase 3 trial of Novartis' Pluvicto (Lu-PSMA-617) in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) as presented at ESMO 2023

Ticker(s): NVS

Who's the expert?

Institution: UCLA

Director of Clinical Research and Associate Professor of Translation Theranostics at UCLA.
Manages 15 patients with metastatic castration resistant prostate cancer.
Research focuses on translatable radiolabeled theranostic pairs that can be applied for diagnosis and therapy of cancer.

Interview Goal

This call will feature an analysis of the current data available regarding Pluvicto as a treatment for metastatic castration resistant prostate cancer, and will also discuss the recent data which was presented at ESMO 2023.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.